Evaluating the Early Efficacy and Safety of Ritlecitinib in Moderate Alopecia Areata: A Real-World, Single-Center Study

This file provides supplementary data for Evaluating the Early Efficacy and Safety of Ritlecitinib in Moderate Alopecia Areata: A Real-World, Single-Center Study. It includes: (1) one illustrative figure demonstrating a representative patient’s clinical response after 16 weeks of treatment, (2) a table summarizing treatment response in eyebrow and eyelash involvement, and (3) a comparative table of baseline demographics and disease characteristics between patients who achieved SALT50 at week 16 and those who did not. These materials support the main findings by offering detailed insights into subgroup responses and potential predictors of efficacy.

本文件为《中度斑秃（Alopecia Areata）患者中利特昔替尼（Ritlecitinib）的早期疗效与安全性评估：一项真实世界单中心研究》提供补充数据。具体内容包括：(1) 1幅说明性图片，展示1例患者接受16周治疗后的典型临床应答情况；(2) 1张汇总眉毛与睫毛受累患者治疗应答情况的表格；(3) 1张对比第16周达到SALT50与未达到SALT50患者的基线人口统计学特征与疾病特征的表格。上述材料通过提供亚组应答与疗效潜在预测因子的详细见解，为主要研究结果提供支撑。